Search the Newsreel

PTC Inc. stock rises Tuesday, still underperforms market

Shares of PTC Inc. (PTC) rose by 1.30% on Tuesday, closing at $141.68, marking its eighth consecutive day of gains. Despite this rise, the stock underperformed the broader market, as the S&P 500 Index and the Dow Jones Industrial Average both saw larger increases.

Pacer Advisors Inc. Has $60.57 Million Stake in PTC Inc. $PTC

Pacer Advisors Inc. significantly increased its stake in PTC Inc. by 243.8% in the first quarter, now holding 425,112 shares valued at approximately $60.6 million. Institutional investors collectively own 95.14% of PTC. The company slightly beat EPS estimates but missed revenue expectations, with analyst …

Private Client Services LLC Makes New $1.22 Million Investment in PTC Inc. $PTC

Private Client Services LLC has invested $1.22 million in PTC Inc. by acquiring 10,753 shares during the second quarter. Despite mixed analyst ratings, with a consensus "Hold" and an average price target of $170.14, PTC's Q2 EPS slightly beat expectations. However, revenue declined 6.8% …

Top 3 Health Care Stocks You'll Regret Missing This Quarter

This article identifies three oversold healthcare stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT), and Indivior Pharmaceuticals (INDV), which recently announced a merger with Supernus Pharmaceuticals. These companies are highlighted due to their Relative Strength Index (RSI) being below 30, indicating they may be undervalued. …

Lombard Odier Asset Management Europe Ltd Sells 54,482 Shares of PTC Inc. $PTC

Lombard Odier Asset Management Europe Ltd significantly reduced its stake in PTC Inc. by selling 54,482 shares, retaining 11,266 shares valued at approximately $1.6 million. Despite this, institutional investors still hold 95.14% of PTC's stock. The company recently reported quarterly earnings that narrowly beat …

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) has seen a 20.3% loss in stock value over the past four weeks, but indicators suggest a potential trend reversal. The stock is currently in oversold territory with an RSI reading of 27.14, and Wall Street analysts have significantly raised their …

Empowered Funds LLC Sells 192,506 Shares of PTC Therapeutics, Inc. $PTCT

Empowered Funds LLC significantly reduced its stake in PTC Therapeutics, Inc. by selling 192,506 shares, retaining 57,906 shares valued at $3.95 million. This divestment occurred despite other major institutions increasing their holdings and PTC Therapeutics reporting strong quarterly results with EPS of $0.92 and …

Berenberg Bank Maintains PTC Inc(PTC.US) With Hold Rating, Maintains Target Price $170

Berenberg Bank has reiterated its Hold rating on PTC Inc (PTC.US), maintaining a target price of $170. This indicates an unchanged outlook on the stock's performance by the bank.

PTC Therapeutics (PTCT) Is Down 11.5% After Raising 2026 Outlook And Boosting Profitability - Has The Bull Case Changed?

PTC Therapeutics reported strong Q2 2026 revenue of US$360.52 million and net income of US$83.5 million, leading to an increased full-year 2026 revenue outlook of US$1.18 billion to US$1.28 billion. Despite this positive financial report, the company's shares experienced an 11.47% weekly decline, prompting …

Price to book forward of PTC Therapeutics, Inc. – BX:P91

This article provides a financial data point for PTC Therapeutics, Inc. (BX:P91), specifically its "Price to book forward." It indicates the value and change for this metric over a specified period. The information is presented within the context of a trading and financial data …

PTC India Financial Services eyes ₹5,000 cr AUM by FY27 end

Discipline and Rules-Based Execution in PTC Response

This article analyzes PTC Inc. (NYSE: PTC) with a focus on rules-based execution and AI-generated trading strategies. It highlights a potential shift in positive near-term sentiment and divergent sentiment across different time horizons, suggesting choppy market conditions. The article provides specific strategies for position …

PTC Therapeutics Inc (PTCT) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

PTC Therapeutics reported record quarterly revenue of $361 million for Q2 2026, driven by strong growth in Sephience revenue and other product sales, leading to a raised full-year product revenue guidance of $850 million to $950 million. The company highlighted positive interim data for …

PTC Therapeutics (PTCT) Stock Drops As Profit Surge Meets Launch Concentration Risk

PTC Therapeutics (PTCT) experienced a nearly 10% stock drop despite a strong Q2 2026 earnings report, which showed a significant revenue increase and a swing to profitability. The company's optimistic outlook relies on the success of Sephience and its pipeline, with Sephience showing strong …

PTC INC. 3Q 2026: Revenue $600M, EPS $1.03— 10-Q Summary

PTC INC. reported its third-quarter 2026 results, showing revenue of $600 million and diluted EPS of $1.03. While revenue declined year-over-year due to a divestiture and lower license timing, the company demonstrated strength in recurring revenue, annual recurring revenue (ARR) growth excluding divested units, …

PTC THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $106 FROM $93

Wells Fargo has increased its target price for PTC Therapeutics, Inc. from $93 to $106. This adjustment reflects an updated valuation for the company. The article, sourced from Reuters, includes a disclaimer noting that the content represents the author's opinion and should not be …

PTC Inc. $PTC Shares Sold by Liontrust Investment Partners LLP

Liontrust Investment Partners LLP significantly reduced its stake in PTC Inc. by 39.6% in the first quarter, selling over 231,000 shares. This comes as other institutional investors have made various adjustments to their holdings in the technology company. Analyst ratings for PTC are mixed, …

Arrowstreet Capital Limited Partnership Cuts Position in PTC Inc. $PTC

Arrowstreet Capital Limited Partnership significantly reduced its stake in PTC Inc. by 28.7% during the first quarter, selling 42,605 shares and bringing its total holdings to 105,797 shares valued at $15.075 million. Other institutional investors have also adjusted their positions in PTC, with several …

PTC Inc. $PTC Shares Purchased by Amundi

Amundi significantly increased its stake in PTC Inc. (NASDAQ:PTC) by 151.9% during the first quarter, now owning 1.49% of the company's shares valued at $245.885 million. Other institutional investors also adjusted their holdings in PTC, which currently has a market cap of $15.74 billion …

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Inc. (NASDAQ: PTC) balances Q3 revenue decline with higher cash flow and ARR

PTC Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:PTC)

PTC Inc. published its Q3 2026 earnings call slide deck. The company reported EPS of $1.58, beating estimates by $0.02, but revenue of $600.05M missed by $12.75M, representing a 6.82% year-over-year decrease. The article was written by SA Transcripts, which publishes thousands of quarterly …

A Quick Look at Today's Ratings for PTC Inc(PTC.US), With a Forecast Between $155 to $195

This article provides an overview of recent analyst ratings for PTC Inc (PTC.US), noting that analysts generally maintain a "Buy" or "Outperform" rating for the company. The price targets range from $155 to $195, indicating a positive outlook for the stock's future performance.

PTC Therapeutics (PTCT) director details stock, options and RSUs

PTC Therapeutics director Hege Elisabeth Sollie-Zetlmayer has reported beneficial ownership of 46,526 shares of common stock, including multiple unvested RSU awards. She also holds several stock options, with three currently exercisable for a total of 65,125 shares at various exercise prices. Additional option grants …

Press Release: PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTC Therapeutics announced its corporate update and second quarter 2026 financial results. The company provided an overview of its operational performance and key financial metrics for the quarter. This release offers insights into PTC Therapeutics' recent business developments and financial standing.

PTC Therapeutics: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for PTC Therapeutics. The content, however, is minimal and appears to be a placeholder or an incomplete article, containing only privacy protection information and image links.

Earnings call transcript: PTC Therapeutics tops Q2 2026 forecasts on strong sales

PTC Therapeutics reported stronger-than-expected Q2 2026 results, with earnings of $0.92 per share and revenue of $361 million, significantly exceeding Wall Street forecasts. The company attributed its record revenue to strong Sephience sales and raised its full-year 2026 revenue guidance to $1.18 billion-$1.28 billion. …

PTC THERAPEUTICS ($PTCT) Releases Q2 2026 Earnings, Stock Rises

PTC Therapeutics (NASDAQ: PTCT) raises 2026 revenue guidance after strong Q2

PTC Therapeutics reported strong Q2 2026 results, achieving a net income of $83.5 million and total revenue of $361 million, significantly improving from a loss in Q2 2025. The company raised its full-year 2026 revenue guidance to $1.18 to $1.28 billion for total revenue …

BMO raises PTC stock price target to $164 on solid results

BMO Capital has increased its price target for PTC Inc. (NASDAQ:PTC) to $164, maintaining an Outperform rating. This upgrade follows PTC’s strong third-quarter results, which surpassed BMO's expectations for annual recurring revenue and free cash flow. The company also raised its fourth-quarter annual recurring …

Quantinno Capital Management LP Buys 194,745 Shares of PTC Inc. $PTC

Quantinno Capital Management LP significantly increased its stake in PTC Inc. by purchasing 194,745 additional shares, bringing its total holdings to 399,056 shares valued at $56.86 million. This comes as PTC Inc. raised its fiscal 2026 guidance, demonstrating strong recurring revenue and free cash …

PTC Therapeutics Inc (PTCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of PTC Therapeutics Inc (PTCT), highlighting its current price momentum, support, and resistance levels. It details various technical indicators like MACD, RSI, and Moving Averages, offering a comprehensive look at the stock's potential short-term movements. The analysis suggests …

PTC Therapeutics, Inc. (NASDAQ: PTCT) posts Q2 2026 profit, Phase 3 HD trial

PTC Therapeutics (NASDAQ:PTCT) Posts Quarterly Earnings Results, Beats Expectations By $0.68 EPS

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

PTC Therapeutics Number of Employees 2026 | Employee Count & Headcount Data

PTC Therapeutics (PTCT) had 988 employees worldwide as of March 2026, a 28.2% decline since 2023. The company is actively hiring, with 45 active job postings in 2026, and its workforce is primarily concentrated in the United States. The article also details employee distribution …